Regeneron To Begin Mass Production Of COVID-19 Treatment Soon


Regeneron scientists work with a bioreactor at a company facility in New York state for efforts on an experimental coronavirus antibody drug. (Regeneron via AP)

Regeneron Pharmaceauticals is gearing up to begin mass manufacturing of its antibody coronavirus treatment, which was administered to President Trump after he tested positive for COVID-19.

On Tuesday, the pharmaceutical company announced it has successfully been able to produce large quantities of the treatment in preparation for when it’s approved by the U.S. Food and Drug Administration (FDA).

“I think we’re right on track and we recently announced that we’re right on track with meeting that commitment,” stated George Yancopoulos, President of Regeneron Pharmaceauticals Inc. “We’ve already produced more than the 50,000 doses.”

The company expects to begin production at the start of 2021 and hopes to produce 2 million doses by the end of the year.

“We’re on track, by January, to fulfill the entire allotment and beyond that, we’re scaling up further in-house,” Yancopoulos continued. “And, of course, we established this very important and productive partnership with Roche Genentech to significantly expand the global capacity.”

The antibody cocktail still needs to be approved by regulators, but Regeneron Pharmaceuticals said they have been in daily talks with the FDA to gain emergency use authorization.



Follow us on twitter (ajuede.com) or on Instagram (ajuedeman) for details of the global situation presently.

Comments

Popular posts from this blog

Dr. Vladimir Zelenko has now treated 699 coronavirus patients with 100% success

ORIGIN OF THE AKAN

GARDEN OF EDEN FOUND IN AFRICA

THE HISTORY AND ORIGIN OF THE ZULU PEOPLE

FIVE WAYS A WIFE CAN REST HER HUSBAND ON HER

BRIEF HISTORY OF NKALAHA.

MYSTERY OF IGBO COSMOLOGY

THE ORIGIN AND HISTORY OF UDI by Onyeji Nnaji

THE ORIGIN AND HISTORY OF NSUKKA by Onyeji Nnaji

ETHIOPIA:THE OLDEST PEOPLE IN THE MIDDLE EAST